dNTP supply gene expression Patterns after P53 loss

Cancers

Volumn 4, Issue 4, 2012, Pages 1212-1224

  Radivoyevitch, Tomas ^a   Saunthararajah, Yogen ^b   Pink, John ^a   Ferris, Gina ^a   Lent, Ian ^a   Jackson, Mark ^a   Junk, Damian ^a   Kunos, Charles A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Deoxycytidine kinase; Deoxyguanosine kinase; dNTP supply and demand; Gene expression; Li Fraumeni; p53; p53R2; Ribonucleotide reductase; Thymidine kinase

Indexed keywords

CELL NUCLEUS DNA; CYTOSOLIC DEOXYCYTIDINE KINASE; DEOXYCYTIDINE KINASE; DEOXYGUANOSINE KINASE; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; MITOCHONDRIAL DNA; PROTEIN P16; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; SMALL INTERFERING RNA; THYMIDINE KINASE; THYMIDINE KINASE 1; THYMIDINE KINASE 2; UNCLASSIFIED DRUG;

ARTICLE; BREAST EPITHELIUM; CANCER CELL; CONTROLLED STUDY; ENZYME ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEADY STATE; WILD TYPE;

EID: 84871554234     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers4041212     Document Type: Article

References (31)

1. Vousden, K.H.; Prives, C. P53 and prognosis: New insights and further complexity. Cell 2005, 120, 7-10.
2. Nakano, K.; Balint, E.; Ashcroft, M.; Vousden, K.H. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 2000, 19, 4283-4289.
3. Heinemann, V.; Xu, Y.Z.; Chubb, S.; Sen, A.; Hertel, L.W.; Grindey, G.B.; Plunkett, W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol. Pharmacol. 1990, 38, 567-572.
4. Jones, P.A.; Taylor, S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980, 20, 85-93.
5. Ng, K.P.; Ebrahem, Q.; Negrotto, S.; Mahfouz, R.Z.; Link, K.A.; Hu, Z.; Gu, X.; Advani, A.; Kalaycio, M.; Sobecks, R et al. p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia 2011, 25, 1739-1750.
6. Shi, J.Y.; Shi, Z.Z.; Zhang, S.J.; Zhu, Y.M.; Gu, B.W.; Li, G.; Bai, X.T.; Gao, X.D.; Hu, J.; Jin, W et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 2004, 14, 759-768.
7. Marechal, R.; Mackey, J.R.; Lai, R.; Demetter, P.; Peeters, M.; Polus, M.; Cass, C.E.; Salmon, I.; Deviere, J.; van Laethem, J.L. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 2010, 116, 5200-5206.
8. Shao, J.; Zhou, B.; Chu, B.; Yen, Y. Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets 2006, 6, 409-431.
9. Barrett, T.; Troup, D.B.; Wilhite, S.E.; Ledoux, P.; Evangelista, C.; Kim, I.F.; Tomashevsky, M.; Marshall, K.A.; Phillippy, K.H.; Sherman, P.M et al. NCBI GEO: Archive for functional genomics data sets-10 years on. Nucleic Acids Res. 2011, 39, D1005-D1010.
10. Herbert, B.S.; Chanoux, R.A.; Liu, Y.; Baenziger, P.H.; Goswami, C.P.; McClintick, J.N.; Edenberg, H.J.; Pennington, R.E.; Lipkin, S.M.; Kopelovich, L. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. Oncotarget 2010, 1, 405-422.
11. Miller, L.D.; Smeds, J.; George, J.; Vega, V.B.; Vergara, L.; Ploner, A.; Pawitan, Y.; Hall, P.; Klaar, S.; Liu, E.T et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 2005, 102, 13550-13555.
12. Zhang, K.; Wu, J.; Wu, X.; Wang, X.; Wang, Y.; Zhou, N.; Kuo, M.L.; Liu, X.; Zhou, B.; Chang, L et al. p53R2 Inhibits the proliferation of human cancer cells in association with cell-cycle arrest. Mol. Cancer Ther. 2011, 10, 269-278.
13. Kunos, C.A.; Waggoner, S.; von Gruenigen, V.; Eldermire, E.; Pink, J.; Dowlati, A.; Kinsella, T.J. Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin. Cancer Res. 2010, 16, 1298-1306.
14. Irizarry, R.A.; Bolstad, B.M.; Collin, F.; Cope, L.M.; Hobbs, B.; Speed, T.P. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003, 31, e15.
15. Gautier, L.; Cope, L.; Bolstad, B.M.; Irizarry, R.A. affy-Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20, 307-315.
16. Garbe, J.C.; Bhattacharya, S.; Merchant, B.; Bassett, E.; Swisshelm, K.; Feiler, H.S.; Wyrobek, A.J.; Stampfer, M.R. Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells. Cancer Res. 2009, 69, 7557-7568.
17. Jackson, M.W.; Agarwal, M.K.; Yang, J.; Bruss, P.; Uchiumi, T.; Agarwal, M.L.; Stark, G.R.; Taylor, W.R. p130/p107/p105Rb-dependent transcriptional repression during DNA-damageinduced cell-cycle exit at G2. J. Cell Sci. 2005, 118, 1821-1832.
18. Brummelkamp, T.R.; Bernards, R.; Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296, 550-553.
19. Gentleman, R.C.; Carey, V.J.; Bates, D.M.; Bolstad, B.; Dettling, M.; Dudoit, S.; Ellis, B.; Gautier, L.; Ge, Y.; Gentry, J et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5, R80.
20. Smyth, G.K. Limma: Linear models for microarray data. In Bioinformatics and Computational Biology Solutions Using R and Bioconductor; Springer: New York, NY, USA, 2005; pp. 397-420.
21. Gentleman, R.C.; Carey, V.J.; Bates, D.M.; Bolstad, B.; Dettling, M.; Dudoit, S.; Ellis, B.; Gautier, L.; Ge, Y.; Gentry, Y et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol. 2004, 5, R80.
22. Bourdon, A.; Minai, L.; Serre, V.; Jais, J.P.; Sarzi, E.; Aubert, S.; Chretien, D.; de Lonlay, P.; Paquis-Flucklinger, V.; Arakawa, H et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat. Genet. 2007, 39, 776-780.
23. Gower, W.R., Jr.; Carr, M.C.; Ives, D.H. Deoxyguanosine kinase. Distinct molecular forms in mitochondria and cytosol. J. Biol. Chem. 1979, 254, 2180-2183.
24. Colly, L.P.; Richel, D.J.; Arentsen-Honders, M.W.; Kester, M.G.; ter Riet, P.M.; Willemze, R. Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway. Ann. Hematol. 1992, 65, 26-32.
25. Bradshaw, P.C.; Samuels, D.C. A computational model of mitochondrial deoxynucleotide metabolism and DNA replication. Am. J. Physiol. Cell Physiol. 2005, 288, C989-C1002.
26. Bryson, A.E.; Ho, Y.C. Applied Optimal Control; Hemisphere Publishing Corporation: New York, NY, USA, 1975.
27. Kailath, T. Linear Systems; Prentice-Hall: Englewood Cliffs, NJ, USA, 1980.
28. Radivoyevitch, T.; Loparo, K.A.; Jackson, R.C.; Sedwick, W.D. On systems and control approaches to therapeutic gain. BMC Cancer 2006, 6, 104.
29. Ainseba, B.; Benosman, C. Optimal control for resistance and suboptimal response in CML. Math. Biosci. 2010, 227, 81-93.
30. Padhi, R.; Kothari, M. An optimal dynamic inversion-based neuro-adaptive approach for treatment of chronic myelogenous leukemia. Comput. Methods Programs Biomed. 2007, 87, 208-224.
31. Nanda, S.; Moore, H.; Lenhart, S. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math. Biosci. 2007, 210, 143-156.